Relationship between circulating miRNA-30e and no-reflow phenomenon in STEMI patients undergoing primary coronary intervention

References

• Brosh D, Assali AR, Mager A, et al. Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality. The American Journal of Cardiology. 2007;99:442–445.
   PubMed Web of Science ®Google Scholar
• Durante A, Camici PG. Novel insights into an “old; phenomenon: the no reflow”. Int J Cardiol. 2015;187:273–280.
   PubMed Web of Science ®Google Scholar
• Celik T, Balta S, Mikhailidis DP, et al. The relation between no-reflow phenomenon and complete blood count parameters. Angiology. 2017;68:381–388.
   PubMed Web of Science ®Google Scholar
• Genda S, Miura T, Miki T, et al. KATP channel opening is an endogenous mechanism of protection against the no-reflow phenomenon but its function is compromised by hypercholesterolemia. J Am Coll Cardiol. 2002;40:1339–1346.
   PubMed Web of Science ®Google Scholar
• Reffelmann T, Kloner RA. The no-reflow phenomenon: a basic mechanism of myocardial ischemia and reperfusion. Basic Res Cardiol. 2006;101:359–372.
   PubMed Web of Science ®Google Scholar
• Hale SL, Kloner RA. The antianginal agent, ranolazine, reduces myocardial infarct size but does not alter anatomic no-reflow or regional myocardial blood flow in ischemia/reperfusion in the rabbit. J Cardiovasc Pharmacol Ther. 2008;13:226–232.
   PubMed Web of Science ®Google Scholar
• Barwari T, Joshi A, Mayr M. MicroRNAs in cardiovascular disease. J Am Coll Cardiol. 2016;68:2577–2584.
   PubMed Web of Science ®Google Scholar
• Jia QW, Chen ZH, Ding XQ, et al. Predictive effects of circulating miR-221, miR-130a and miR-155 for coronary heart disease: a multi-ethnic study in China. Cell Physiol Biochem. 2017;42:808–823.
   PubMed Web of Science ®Google Scholar
• Leger KJ, Leonard D, Nielson D, et al. Circulating microRNAs: potential markers of cardiotoxicity in children and young adults treated with anthracycline chemotherapy. J Am Heart Assoc. 2017;6:e004653.
   PubMed Web of Science ®Google Scholar
• Vegter EL, Schmitter D, Hagemeijer Y, et al. Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. Int J Cardiol. 2016;224:231–239.
   PubMed Web of Science ®Google Scholar
• Wang X, Wu X, Lu Y, et al. Potential involvement of MiR-30e-3p in myocardial injury induced by coronary microembolization via autophagy activation. Cell Physiol Biochem. 2017;44:1995–2004.
   PubMed Web of Science ®Google Scholar
• Charron T, Jaffe R, Segev A, et al. Effects of distal embolization on the timing of platelet and inflammatory cell activation in interventional coronary no-reflow. Thrombosis Res. 2010;126:50–55.
   PubMed Web of Science ®Google Scholar
• Dörr M, Vogelgesang D, Hummel A, et al. Excimer laser thrombus elimination for prevention of distal embolization and no-reflow in patients with acute ST elevation myocardial infarction: results from the randomized LaserAMIstudy. Int J Cardiol. 2007;116:20–26.
   PubMed Web of Science ®Google Scholar
• Dahm JB, Ebersole D, Das T, et al. Prevention of distal embolization and no‐reflow in patients with acute myocardial infarction and total occlusion in the infarct‐related vessel: a subgroup analysis of the cohort of acute revascularization in myocardial infarction with excimer laser—CARMEL multicenter study. Cathet Cardiovasc Intervent. 2005;64:67–74.
   PubMed Web of Science ®Google Scholar
• Kurtul A, Acikgoz SK. Usefulness of mean platelet volume-to-lymphocyte ratio for predicting angiographic no-reflow and short-term prognosis after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. Am J Cardiol. 2017;120:534–541.
   PubMed Web of Science ®Google Scholar
• Kurtul A, Yarlioglues M, Celik IE, et al. Association of lymphocyte-to-monocyte ratio with the no-reflow phenomenon in patients who underwent a primary percutaneous coronary intervention for ST-elevation myocardial infarction. Coron Artery Dis. 2015;26:706–712.
   PubMed Web of Science ®Google Scholar
• Kobat MA, Balin M, Celik A, et al. The relationship between platelet collagen receptor glycoprotein vi and no-reflow phenomenon in patients with acute st-segment elevation myocardial infarction. J Investig Med. 2014;62:62–70.
   PubMed Web of Science ®Google Scholar
• Akpek M, Kaya MG, Lam YY, et al. Relation of neutrophil/lymphocyte ratio to coronary flow to in-hospital major adverse cardiac events in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Am J Cardiol. 2012;110:621–627.
   PubMed Web of Science ®Google Scholar
• Celık T, Balta S, Demır M, et al. Predictive value of admission red cell distribution width-platelet ratio for no-reflow phenomenon in acute ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Cardiol J. 2016;23:84–92.
   PubMed Web of Science ®Google Scholar
• Botto N, Sbrana S, Trianni G, et al. An increased platelet–leukocytes interaction at the culprit site of coronary artery occlusion in acute myocardial infarction: A pathogenic role for “no-reflow” phenomenon? Int J Cardiol. 2007;117:123–130.
   PubMed Web of Science ®Google Scholar
• Hale SL, Kloner RA. Dabigatran treatment: effects on infarct size and the no-reflow phenomenon in a model of acute myocardial ischemia/reperfusion. J Thromb Thrombolysis. 2015;39:50–54.
   PubMed Web of Science ®Google Scholar
• Celik T, Balta S, Ozturk C, et al. Predictors of no-reflow phenomenon in young patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Angiology. 2016;67:683–689.
   PubMed Web of Science ®Google Scholar
• Su Q, Li L, Zhao J, et al. Effects of Trimetazidine on PDCD4/NF-κB/TNF-α Pathway in Coronary Microembolization. Cell Physiol Biochem. 2017;42:753–760.
   PubMed Web of Science ®Google Scholar
• Su Q, Li L, Wang J, et al. Mechanism of programmed cell death factor 4/nuclear factor-κB signaling pathway in porcine coronary micro-embolization-induced cardiac dysfunction. Exp Biol Med (Maywood). 2015;240:1426–1433.
   PubMed Web of Science ®Google Scholar
• Li L, Li DH, Qu N, et al. The role of ERK1/2 signaling pathway in coronary microembolization-induced rat myocardial inflammation and injury. Cardiology. 2010;117:207–215.
   PubMed Web of Science ®Google Scholar
• Chistiakov DA, Orekhov AN, Bobryshev YV. The role of miR-126 in embryonic angiogenesis, adult vascular homeostasis, and vascular repair and its alterations in atherosclerotic disease. J Mol Cell Cardiol. 2016;97:47–55.
   PubMed Web of Science ®Google Scholar
• Distel E, Barrett TJ, Chung K, et al. miR33 inhibition overcomes deleterious effects of diabetes mellitus on atherosclerosis plaque regression in MiceNovelty and significance. Circul Res. 2014;115:759–769.
   PubMed Web of Science ®Google Scholar
• Viereck J, Thum T. Circulating noncoding RNAs as biomarkers of cardiovascular disease and injury. Circ Res. 2017;120:381–399.
   PubMed Web of Science ®Google Scholar
• Su Q, Li L, Zhao J, et al. MiRNA expression profile of the myocardial tissue of pigs with coronary microembolization. Cell Physiol Biochem. 2017;43:1012–1024.
   PubMed Web of Science ®Google Scholar